Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies

Những quyển sách tương tự

• Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial
  Bằng: Mathieu, Chantal, et al.
  Được phát hành: (2020)
• Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
  Bằng: Araki, Eiichi, et al.
  Được phát hành: (2021)
• Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)
  Bằng: Mathieu, Chantal, et al.
  Được phát hành: (2020)
• SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes
  Bằng: Mathieu, Chantal, et al.
  Được phát hành: (2019)
• Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial
  Bằng: Araki, Eiichi, et al.
  Được phát hành: (2019)